DeuterOncology is developing less invasive therapeutic approaches for lung cancer. The company has reported initial encouraging results from early clinical testing. It has raised €5 million to continue and expand those clinical trials to a larger panel of patients. DeuterOncology plans to use the new funding to confirm efficacy and safety in broader studies. The articles do not provide revenue, user metrics, founding year, or detailed financial history.

Total raised

$12M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2026